Market Overview

MannKind Satisfies Conditions for Second Tranche of Convertible Notes Financing

Related MNKD
Benzinga's Top #PreMarket Gainers
Earnings Scheduled For November 3, 2014
MannKind: FDA Delays Afrezza Decision by Three Months (Fox Business)

MannKind Corporation (Nasdaq: MNKD) today announced that, pursuant to a Facility Agreement (the “Facility Agreement”) dated July 1, 2013 between Deerfield Private Design Fund II, L.P. and Deerfield Private Design International II, L.P. (collectively, “Deerfield”) and MannKind, the conditions that obligate Deerfield to purchase the second $40 million tranche of 9.75% senior secured convertible notes (the “Convertible Notes”) have now been satisfied. The second tranche of Convertible Notes was subject to the achievement of Phase 3 data from studies 171 and 175 that met the primary efficacy endpoints of these studies and did not show any adverse safety issue that would reasonably be expected to prevent approval of AFREZZA. The Facility Agreement provides that Deerfield is obligated to purchase up to four equal tranches of Convertible Notes for total gross proceeds of up to $160 million. The closing of the second tranche is expected to occur no later than September 6, 2013.

Posted-In: News Financing

 

Related Articles (MNKD)

Around the Web, We're Loving...

Get Benzinga's Newsletters